NL8700285A - Vaccinpreparaten. - Google Patents
Vaccinpreparaten. Download PDFInfo
- Publication number
- NL8700285A NL8700285A NL8700285A NL8700285A NL8700285A NL 8700285 A NL8700285 A NL 8700285A NL 8700285 A NL8700285 A NL 8700285A NL 8700285 A NL8700285 A NL 8700285A NL 8700285 A NL8700285 A NL 8700285A
- Authority
- NL
- Netherlands
- Prior art keywords
- virus
- protein
- peptide
- recombinant
- cells
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 86
- 238000002360 preparation method Methods 0.000 title claims description 35
- 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 claims description 321
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 claims description 321
- 210000004027 cell Anatomy 0.000 claims description 156
- 108090000623 proteins and genes Proteins 0.000 claims description 156
- 102000036639 antigens Human genes 0.000 claims description 119
- 108091007433 antigens Proteins 0.000 claims description 119
- 241000700605 Viruses Species 0.000 claims description 115
- 239000000427 antigen Substances 0.000 claims description 115
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 111
- 102000004169 proteins and genes Human genes 0.000 claims description 103
- 201000001441 melanoma Diseases 0.000 claims description 67
- 241000700618 Vaccinia virus Species 0.000 claims description 42
- 230000014509 gene expression Effects 0.000 claims description 40
- 239000013598 vector Substances 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 30
- 230000002163 immunogen Effects 0.000 claims description 29
- 239000002773 nucleotide Substances 0.000 claims description 27
- 125000003729 nucleotide group Chemical group 0.000 claims description 27
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 230000000890 antigenic effect Effects 0.000 claims description 20
- 108020004511 Recombinant DNA Proteins 0.000 claims description 17
- 230000002458 infectious effect Effects 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 11
- 210000004748 cultured cell Anatomy 0.000 claims description 8
- 229940031626 subunit vaccine Drugs 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 241000701161 unidentified adenovirus Species 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 5
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims 16
- 102100037364 Craniofacial development protein 1 Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 313
- 235000018102 proteins Nutrition 0.000 description 78
- 206010028980 Neoplasm Diseases 0.000 description 68
- 239000002299 complementary DNA Substances 0.000 description 67
- 102000004196 processed proteins & peptides Human genes 0.000 description 56
- 108020004999 messenger RNA Proteins 0.000 description 54
- 150000001413 amino acids Chemical group 0.000 description 52
- 241000699670 Mus sp. Species 0.000 description 45
- 238000000034 method Methods 0.000 description 45
- 238000013519 translation Methods 0.000 description 32
- 239000013604 expression vector Substances 0.000 description 31
- 239000012634 fragment Substances 0.000 description 31
- 230000014616 translation Effects 0.000 description 31
- 239000000047 product Substances 0.000 description 25
- 210000004881 tumor cell Anatomy 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 22
- 230000028993 immune response Effects 0.000 description 22
- 239000002609 medium Substances 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 20
- 102000004338 Transferrin Human genes 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 239000012581 transferrin Substances 0.000 description 19
- 108090000901 Transferrin Proteins 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 18
- 230000003053 immunization Effects 0.000 description 18
- 238000003780 insertion Methods 0.000 description 18
- 230000037431 insertion Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 206010046865 Vaccinia virus infection Diseases 0.000 description 17
- 238000010367 cloning Methods 0.000 description 17
- 208000007089 vaccinia Diseases 0.000 description 17
- 238000002649 immunization Methods 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 108091026890 Coding region Proteins 0.000 description 14
- 210000002729 polyribosome Anatomy 0.000 description 14
- 238000013459 approach Methods 0.000 description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
- 108020004705 Codon Proteins 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 108020004440 Thymidine kinase Proteins 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 210000003527 eukaryotic cell Anatomy 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 238000001114 immunoprecipitation Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000004989 spleen cell Anatomy 0.000 description 8
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 8
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- 102000006601 Thymidine Kinase Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 239000013600 plasmid vector Substances 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 6
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 238000010804 cDNA synthesis Methods 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 230000007969 cellular immunity Effects 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229960004854 viral vaccine Drugs 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 4
- 101000940535 Homo sapiens Cold shock domain-containing protein E1 Proteins 0.000 description 4
- 101001034811 Homo sapiens Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 4
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 4
- 101000834991 Homo sapiens Transitional endoplasmic reticulum ATPase Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 241000282553 Macaca Species 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 108010033576 Transferrin Receptors Proteins 0.000 description 4
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000003277 amino acid sequence analysis Methods 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 102000046317 human CSDE1 Human genes 0.000 description 4
- -1 i.e. Proteins 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 210000001995 reticulocyte Anatomy 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000005951 type IV hypersensitivity Effects 0.000 description 4
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 238000007900 DNA-DNA hybridization Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 102000003792 Metallothionein Human genes 0.000 description 3
- 108090000157 Metallothionein Proteins 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229940031551 inactivated vaccine Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 229940031348 multivalent vaccine Drugs 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102000007365 Sialoglycoproteins Human genes 0.000 description 2
- 108010032838 Sialoglycoproteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229910052793 cadmium Inorganic materials 0.000 description 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 230000010438 iron metabolism Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000353621 Eilat virus Species 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000004729 Feline Leukemia Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000714188 Friend murine leukemia virus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001417501 Lobotidae Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 101001034810 Mus musculus Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000714223 Rauscher murine leukemia virus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000000479 TCF Transcription Factors Human genes 0.000 description 1
- 108010016283 TCF Transcription Factors Proteins 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 208000011586 benign melanocytic skin nevus Diseases 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000050459 human LTF Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940115256 melanoma vaccine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 101150073640 ompF gene Proteins 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 230000001402 polyadenylating effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82731386A | 1986-02-07 | 1986-02-07 | |
| US82731386 | 1986-02-07 | ||
| US723087 | 1987-01-27 | ||
| US07/007,230 US5262177A (en) | 1986-02-07 | 1987-01-27 | Recombinant viruses encoding the human melanoma-associated antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8700285A true NL8700285A (nl) | 1987-09-01 |
Family
ID=26676698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8700285A NL8700285A (nl) | 1986-02-07 | 1987-02-06 | Vaccinpreparaten. |
Country Status (18)
| Country | Link |
|---|---|
| JP (3) | JP2664673B2 (de) |
| BE (1) | BE1000175A3 (de) |
| CH (1) | CH675424A5 (de) |
| DE (1) | DE3703702C2 (de) |
| DK (1) | DK63287A (de) |
| ES (2) | ES2012815A6 (de) |
| FI (1) | FI94836C (de) |
| GR (1) | GR870195B (de) |
| HU (1) | HU209144B (de) |
| IE (1) | IE59597B1 (de) |
| IT (1) | IT1222359B (de) |
| MX (1) | MX9203574A (de) |
| NL (1) | NL8700285A (de) |
| NO (1) | NO178931C (de) |
| NZ (1) | NZ219192A (de) |
| OA (1) | OA08478A (de) |
| PT (1) | PT84255B (de) |
| SE (2) | SE506024C2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19821925A1 (de) * | 1998-05-15 | 1999-11-18 | Roehnisch Tim | Verfahren zur Herstellung einer Zusammensetzung zur Induktion einer tumorspezifischen Immunantwort, sowie Verwendung der Zusammensetzung zur Behandlung von Neoplasien |
| JP4414023B2 (ja) * | 1999-08-05 | 2010-02-10 | オリエンタル酵母工業株式会社 | 関節炎関連メラノトランスフェリンの測定方法および試薬 |
| JP4708027B2 (ja) * | 2002-10-01 | 2011-06-22 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法 |
| US8207314B2 (en) * | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
-
1987
- 1987-02-05 NZ NZ219192A patent/NZ219192A/xx unknown
- 1987-02-06 IT IT19291/87A patent/IT1222359B/it active
- 1987-02-06 GR GR870195A patent/GR870195B/el unknown
- 1987-02-06 FI FI870501A patent/FI94836C/fi not_active IP Right Cessation
- 1987-02-06 ES ES8700288A patent/ES2012815A6/es not_active Expired - Fee Related
- 1987-02-06 DK DK063287A patent/DK63287A/da not_active Application Discontinuation
- 1987-02-06 NO NO870475A patent/NO178931C/no unknown
- 1987-02-06 BE BE8700094A patent/BE1000175A3/fr not_active IP Right Cessation
- 1987-02-06 DE DE3703702A patent/DE3703702C2/de not_active Expired - Fee Related
- 1987-02-06 SE SE8700466A patent/SE506024C2/sv not_active IP Right Cessation
- 1987-02-06 IE IE31987A patent/IE59597B1/en not_active IP Right Cessation
- 1987-02-06 NL NL8700285A patent/NL8700285A/nl not_active Application Discontinuation
- 1987-02-06 OA OA59065A patent/OA08478A/xx unknown
- 1987-02-06 JP JP62026191A patent/JP2664673B2/ja not_active Expired - Lifetime
- 1987-02-06 HU HU87472A patent/HU209144B/hu not_active IP Right Cessation
- 1987-02-06 PT PT84255A patent/PT84255B/pt not_active IP Right Cessation
- 1987-02-09 CH CH471/87A patent/CH675424A5/de not_active IP Right Cessation
-
1989
- 1989-06-15 ES ES8902106A patent/ES2017258A6/es not_active Expired - Fee Related
-
1992
- 1992-06-26 MX MX9203574A patent/MX9203574A/es not_active Application Discontinuation
- 1992-10-07 SE SE9202934A patent/SE9202934D0/xx unknown
-
1996
- 1996-03-12 JP JP8054929A patent/JPH08280390A/ja active Pending
- 1996-03-12 JP JP8054928A patent/JPH09135692A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI870501A (fi) | 1987-08-08 |
| IE59597B1 (en) | 1994-03-09 |
| SE8700466D0 (sv) | 1987-02-06 |
| HUT43107A (en) | 1987-09-28 |
| HU209144B (en) | 1994-03-28 |
| DK63287A (da) | 1987-08-08 |
| FI94836B (fi) | 1995-07-31 |
| IE870319L (en) | 1987-08-07 |
| JP2664673B2 (ja) | 1997-10-15 |
| IT8719291A0 (it) | 1987-02-06 |
| NZ219192A (en) | 1991-10-25 |
| DK63287D0 (da) | 1987-02-06 |
| GR870195B (en) | 1987-06-10 |
| FI94836C (fi) | 1995-11-10 |
| NO178931C (no) | 1996-07-03 |
| JPH09135692A (ja) | 1997-05-27 |
| PT84255B (pt) | 1989-11-30 |
| SE506024C2 (sv) | 1997-11-03 |
| BE1000175A3 (fr) | 1988-07-12 |
| DE3703702C2 (de) | 1997-07-10 |
| JPH08280390A (ja) | 1996-10-29 |
| CH675424A5 (en) | 1990-09-28 |
| OA08478A (fr) | 1988-07-29 |
| PT84255A (en) | 1987-03-01 |
| IT1222359B (it) | 1990-09-05 |
| NO178931B (no) | 1996-03-25 |
| NO870475L (no) | 1987-08-10 |
| FI870501A0 (fi) | 1987-02-06 |
| NO870475D0 (no) | 1987-02-06 |
| ES2017258A6 (es) | 1991-01-16 |
| ES2012815A6 (es) | 1990-04-16 |
| JPS62294698A (ja) | 1987-12-22 |
| DE3703702A1 (de) | 1988-02-18 |
| SE8700466L (sv) | 1987-08-08 |
| SE9202934D0 (sv) | 1992-10-07 |
| MX9203574A (es) | 1992-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5262177A (en) | Recombinant viruses encoding the human melanoma-associated antigen | |
| US5141742A (en) | Vaccines against melanoma | |
| DE69533295T2 (de) | Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma | |
| JP3051130B2 (ja) | 組換えコクシジウム症ワクチン類 | |
| CN87100603A (zh) | 抗黑素瘤疫苗 | |
| JP2852515B2 (ja) | ベクターウイルスおよびベクターウイルスを含む薬用組成物 | |
| WO1992005248A1 (en) | Human papilloma viral protein expression for use in vaccine compositions | |
| JPH08505878A (ja) | 免疫原のリソソーム標的 | |
| JP2007297398A (ja) | 突然変異上皮成長因子受容体を標的とする試薬および方法 | |
| GB2188637A (en) | Vaccines against melanoma | |
| US6551586B1 (en) | Malaria vaccine based upon the addition of a MSA1 peptide | |
| JP3215692B2 (ja) | 組み換えコクシジウム症ワクチン | |
| JP3450018B2 (ja) | コクシジウム症ワクチン | |
| JP3262787B2 (ja) | 豚コレラウイルスワクチン | |
| NL8700285A (nl) | Vaccinpreparaten. | |
| CA2067469C (en) | Recombinant vaccine against marek's disease | |
| KR100768051B1 (ko) | 간염 바이러스 ｏｒｆ2의 ｎ-말단 영역으로부터 유래한프로세싱 성분 및 항원성 폴리펩티드를 암호화하는 핵산구성물 | |
| JPH08502402A (ja) | マラリア寄生虫のための伝播遮断抗体の標的抗原 | |
| PH25991A (en) | Antibodies to novel polypeptide having growth factor activity | |
| JPH03504802A (ja) | 特定のウイルス感染に対する細胞毒性剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |